With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...

Trinity Biotech (TRIB) announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive finan ...

The stock has a market cap of $12.48 million, a PE ratio of -0.31 and a beta of 1.20. Trinity Biotech has a twelve month low of $0.63 and a twelve month high of $3.55. An institutional investor ...

Trinity Biotech PLC (NASDAQ:TRIB), a leading diagnostic substances company with a market capitalization of $13.12 million, has successfully amended and restated its credit and guaranty agreement ...

Shares of TRIB opened at $0.76 on Friday. Trinity Biotech has a twelve month low of $0.74 and a twelve month high of $3.55. The stock has a market cap of $13.72 million, a PE ratio of -0.34 and a ...

DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, ...

Trinity Biotech PLC (TRIB) reports a 3% revenue increase and outlines strategic initiatives for future growth and profitability. Trinity Biotech PLC (TRIB) reports a 14% revenue increase with ...

John Gillard, CEO of Trinity Biotech, emphasized that their patented technology is set to disrupt the CGM market, which is expected to surpass $20 billion by 2029. He highlighted the ergonomic ...